Omaveloxolone (RTA-408)

Omaveloxolone (RTA-408) is an activator of NRF2 and NF-kB used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. It is especially relevant in immunology, inflammation, and oxidative stress models, where defined compound exposure can be linked to inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses.

By activating NRF2 and NF-kB, Omaveloxolone (RTA-408) can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The signaling pathway modulator annotation adds relevance to pathway-reporter and mechanistic-phenotyping studies, together with downstream-response mapping in the same experimental setting. In immunology, inflammation, and oxidative stress models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving NRF2 and NF-kB
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Gain-of-function pathway-activation studies
• Pathway-reporter and mechanistic-phenotyping studies

Overall, Omaveloxolone (RTA-408) is appropriate when a defined chemical perturbant is needed to connect NRF2 and NF-kB with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in immunology, inflammation, and oxidative stress models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.